Stoke Therapeutics: Vulnerable To Profit Taking
Source: SeekingAlpha
2025-08-27 10:06:16 ET
Shares of RNA medicine concern Stoke Therapeutics, Inc. ( STOK ) have more than tripled off their recent lows in early April. Stoke's antisense oligonucleotide zorevunersen has demonstrated significant seizure reduction in Dravet syndrome patients to date, prompting a Breakthrough Therapy designation from the FDA. With an operating runway into mid-2028, a recently inked commercialization deal with Biogen for zorevunersen ex-North America, but no new data until YE27, this clinical-stage biotech name merited a deeper dive. An analysis/recommendation follows below....
Read the full article on Seeking Alpha
For further details see:
Stoke Therapeutics: Vulnerable To Profit Taking
Stoke Therapeutics Inc.
NASDAQ: STOK
STOK Trading
-7.55% G/L:
$33.31 Last:
418,043 Volume:
$36.80 Open:
STOK Latest News
March 04, 2026 05:06:00 pm
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
February 24, 2026 04:01:00 pm
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 11, 2026 07:30:00 am
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
February 04, 2026 04:01:00 pm
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
STOK Stock Data
$1,859,163,232
44,494,260
1.78%
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Bedford
